Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Ten brokerages give Capricor a consensus rating of "Moderate Buy" (nine buy, one sell) with an average 12‑month target of $46.09 and several firms setting higher targets up to $63.
• Insider selling: Company insiders sold 147,529 shares worth $4.51M in the past three months (including the CFO’s sale of 25,000 shares and a director’s sale of 61,265), leaving insiders with 10.50% ownership.
• Business and recent results: Capricor is a clinical‑stage biotech developing CAP‑1002 for indications like DMD and COVID‑19 heart injury; the stock (market cap ~$2.01B) opened at $34.72 after reporting a quarterly loss of $0.62 per share, missing estimates.

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $46.0909.

Several research analysts have recently commented on CAPR shares. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, January 11th. Weiss Ratings reissued a "sell (e+)" rating on shares of Capricor Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an "overweight" rating in a report on Friday, March 13th. HC Wainwright reissued a "buy" rating and set a $60.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, March 10th. Finally, B. Riley Financial boosted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a report on Friday, March 13th.

Capricor Therapeutics Stock Up 0.5%

CAPR stock opened at $34.72 on Wednesday. The firm has a market capitalization of $2.01 billion, a PE ratio of -15.36 and a beta of 0.48. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The stock has a 50-day simple moving average of $28.70 and a two-hundred day simple moving average of $20.47.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). On average, equities research analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the firm's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the sale, the chief financial officer owned 8,223 shares in the company, valued at $247,758.99. This trade represents a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Karimah Es Sabar sold 61,265 shares of the firm's stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 147,529 shares of company stock worth $4,509,940. 10.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently added to or reduced their stakes in CAPR. Farther Finance Advisors LLC purchased a new stake in Capricor Therapeutics in the third quarter worth approximately $28,000. Parkside Financial Bank & Trust purchased a new stake in Capricor Therapeutics in the third quarter worth approximately $36,000. Russell Investments Group Ltd. boosted its stake in Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock worth $37,000 after buying an additional 2,786 shares in the last quarter. ACT Capital Management LLC purchased a new stake in Capricor Therapeutics in the fourth quarter worth approximately $43,000. Finally, GoalVest Advisory LLC purchased a new stake in Capricor Therapeutics in the fourth quarter worth approximately $59,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.